We also present a novel therapeutic approach using CD133 + Exo not only to improve neurological and cognitive outcome post-stroke in T2DM mice but also to reduce the progression of NAFLD/NASH after stroke. This evidence concerns the gene PROM1 and type 2 diabetes mellitus.